|
Return to Contents in this
Issue |
|
|
 Supplement |
|
Interactions of the H1 antihistamines |
|
|
|
J Bartra 1, AL Valero
1, A del Cuvillo 2, I Dávila
3, I Jáuregui 4, J Montoro 5,
J Mullol 6, J Sastre 7 |
|
1 Unitat d’Al·lèrgia. Servei de
Pneumologia i Al·lèrgia Respiratòria. Hospital Clínic (ICT).
Barcelona, Spain;
2 Clínica Dr. Lobatón. Cádiz, Spain;
3 Servicio de Alergia. Hospital Clínico. Salamanca,
Spain;
4 Unidad de Alergología. Hospital de Basurto. Bilbao,
Spain;
5 Unidad de Alergia. Hospital La Plana. Villarreal
(Castellón), Spain;
6 Unitat de Rinologia, Servei d’Otorinolaringologia (ICEMEQ).
Hospital Clínic. Barcelona, Spain;
7 Servicio de Alergia. Fundación Jiménez Díaz. Madrid,
Spain |
|
J Investig Allergol Clin Immunol
2006; Vol. 16, Supplement 1: 29-36 |
|
|
|
Abstract |
|
An interaction is
taken to be the
situation in which
the administration
of a drug or
substance induces
changes in the
pharmacokinetics of
another
simultaneously
administered drug –
either increasing or
decreasing the
plasma concentration
of the latter, and
thus giving rise to
the possibility of
adverse reactions
[1].
According to the
primarily
responsible
pharmacological
mechanism, H1
antihistamine
interactions are
fundamentally of a
pharmacokinetic
nature: the
triggering drug or
substance induces
changes in the
absorption and/ or
metabolism of the H1
antihistamine [2].
Interactions of a
pharmacodynamic
nature, i.e.,
corresponding to
those
situations in which
the actions of the
drug or substance
upon its target
tissues induce
modifi cations in
the actions of
another drug, have
not been reported to
date.
The interactions
described to date
between the H1
antihistamines and
other drugs or
substances
fundamentally take
place via three
different routes:
the P450 cytochrome
system; P
glycoprotein (PgP);
and the members of
the organic anion
transport
polypeptide (OATP)
family..
.../...
more at PDF full
text
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
